EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Therapeutic Potential of a Natural Blend of Aronia melancarpa, Lonicera caerulea, and Echinacea purpurea Extracts in Treating Upper Respiratory Tract Infections: Preliminary Clinical and In Vitro Immunomodulatory Insights

Katarzyna Zima iD, Marta Sochocka iD, Michał Ochnik, Barbara Khaidakov iD, Krzysztof Lemke iD, Paulina Kowalczyk iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms252413436 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Katarzyna Zima und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Medical University of Gdańsk, Dębinki Street 1, 80-211 Gdańsk, Poland. Hauptthemen laut MEDLINE: Plant Extracts, Respiratory Tract Infections, Lonicera, Echinacea. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Centre for Research and Development (Narodowe Centrum Badań i Rozwoju), European Union through the European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upper respiratory tract infections (URTIs) are a prevalent health issue, causing considerable morbidity. Despite the availability of conventional treatments, there is an increasing interest in natural products due to their potential antiviral and immunomodulatory benefits. This study aims to evaluate the efficacy of an ELA blend (E—Echinacea purpurea, L—Lonicera cerulea, A—Aronia melanocarpa) in preventing and alleviating the symptoms of URTIs. Additionally, the study examines the blend’s antiviral and immunomodulatory effects both in vitro and through a clinical trial. A randomized, double-blind, placebo-controlled trial involved 61 participants prone to URTIs, with a 60-day treatment and follow-up period. A placebo group later received the ELA blend for 60 days. The ELA blend significantly reduced the incidence of URTIs during the observation period (2 vs. 8; p = 0.044) and, in particular, throat-related symptoms (8 vs. 16; p = 0.038). Analyses of PBMCs showed that baseline production of the cytokines IFN-γ (p = 0.020), IL-1β (p = 0.004), IL-2(p < 0.001), IL-6 (p < 0.001), and TNF-α (p < 0.001) increased after ELA blend treatment. Moreover, the ELA blend modulated cytokine production in response to PHA-L stimulation, decreasing IFN-γ (p = 0.008) and IL-2 (p = 0.012) while increasing IL-1β (p = 0.005). Following R848 stimulation, the ELA blend enhanced the production of INF-α (p = 0.012) and IL-2 (p = 0.025), and decreased IL-1β (p < 0.001), IL-6 (p < 0.001), and TNF-α (p = 0.049). The blend suppressed VSV replication and significantly increased cytokine levels, with IFN-γ increasing by 98 pg/mL (p = 0.002), IL-1β rising by 233.0 pg/mL (p = 0.004), and TNF-α showing an increase of 2905 pg/mL (p = 0.002). These findings highlight the ELA blend’s potential to alleviate URTI symptoms, modulate inflammatory and antiviral immune responses, and inhibit viral replication. Further investigations should aim to validate these findings through large-scale studies, and explore the ELA blend’s long-term safety and efficacy in diverse populations. Additionally, research should investigate optimal dosing strategies and explore potential synergistic effects with conventional treatments to maximize clinical outcomes. Trial registration: retrospectively registered under NCT06020001.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plant ExtractsRespiratory Tract InfectionsLoniceraEchinaceaCytokinesHumansMaleFemaleAdultMiddle AgedDouble-Blind MethodImmunomodulating AgentsAntiviral AgentsLeukocytes, MononuclearImmunologic Factors

Stichwörter der Autor:innen

AsteraceaeCaprifoliaceaeRosaceaeantiviralimmunomodulatorypolyphenols

Substanzen

Plant ExtractsCytokinesImmunomodulating AgentsAntiviral AgentsImmunologic Factors

Autor:innen und Institutionen

  • Department of Physiology, Medical University of Gdańsk, Dębinki Street 1, 80-211 Gdańsk, Poland.
  • Laboratory of Virology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla Street 12, 53-114 Wrocław, Poland.
  • R&D Department, AronPharma Ltd., Trzy Lipy Street 3, 80-172 Gdańsk, Poland.
  • 3P-Medicine Laboratory, Medical University of Gdańsk, Dębinki Street 7, 80-211 Gdańsk, Poland.

ORCID-Profile: Katarzyna Zima, Marta Sochocka, Barbara Khaidakov, Krzysztof Lemke, Paulina Kowalczyk

Förderung

  • The National Centre for Research and Development (Narodowe Centrum Badań i Rozwoju)
  • European Union through the European Regional Development Fund

Zitieren

APA

Zima, K., Sochocka, M., Ochnik, M., Khaidakov, B., Lemke, K., & Kowalczyk, P. (2024). Therapeutic Potential of a Natural Blend of Aronia melancarpa, Lonicera caerulea, and Echinacea purpurea Extracts in Treating Upper Respiratory Tract Infections: Preliminary Clinical and In Vitro Immunomodulatory Insights. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252413436

Vancouver

Zima K, Sochocka M, Ochnik M, Khaidakov B, Lemke K, Kowalczyk P. Therapeutic Potential of a Natural Blend of Aronia melancarpa, Lonicera caerulea, and Echinacea purpurea Extracts in Treating Upper Respiratory Tract Infections: Preliminary Clinical and In Vitro Immunomodulatory Insights. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252413436

BibTeX
@article{Zima2024,
  author = {Zima, Katarzyna and Sochocka, Marta and Ochnik, Michał and Khaidakov, Barbara and Lemke, Krzysztof and Kowalczyk, Paulina},
  title = {Therapeutic Potential of a Natural Blend of Aronia melancarpa, Lonicera caerulea, and Echinacea purpurea Extracts in Treating Upper Respiratory Tract Infections: Preliminary Clinical and In Vitro Immunomodulatory Insights},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms252413436}
}
Kostenlos starten →